Dicot has submitted a new patent application
News: Uppsala, October 17, 2022. Dicot AB announces today that the company has submitted a new patent application to the Patent and Registration Office. This is according to the IP plan previously communicated by the company. New patents provide 20 years of market exclusivity from the time an application is submitted.
Dicot is developing a new potency drug, LIB-01, which aims to become the first choice for the treatment of erectile dysfunction and premature ejaculation. The company announced earlier this year that it has identified new patent opportunities for LIB-01 and that a new patent application is being prepared.
Today, the company announces that the new patent application has been submitted. It includes both new production methods and intermediates (various chemical compounds) during the manufacture of the drug substance. A major advantage of the new manufacturing method is that it increases the yield.
"A new patent that provides market exclusivity until at least 2042 on a global market, will greatly increase the long-term value of LIB-01. This demonstrates that we deliver according to our IP plan and strategy", says Elin Trampe, CEO at Dicot.
For further information, please contact:
Elin Trampe, CEO
Tel: +46 739 80 14 08
Email: [email protected]
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.
Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit www.dicot.se.
Om Dicot
Dicot utvecklar ett modernt potensläkemedel som ska behandla erektionssvikt och för tidig utlösning bättre än befintliga preparat.
Handelsinformation
IR-Kontakt
